Current stock page

Catalysts

DYN Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

DYNDyne Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$17.16+$0.15 (+0.88%)

Latest quote

  • Momentum
    52
  • Value
    —
  • Quality
    47
  • Risk resilience
    42
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 1, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 48/100

Momentum 52/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 19.88%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 52/100AIQ Edge 8/10 Strong Relative Position
Beat rate
50%
4 of 8 reported periods
Average surprise
-8.1%
Across covered historical reports
Latest result
-16.8%
Nov 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 5, 2026—-$0.91-$1.06-16.8%——
Jul 30, 2026—-$0.75-$1.08-44.2%——
May 11, 2026—-$0.77-$0.73+5.5%——
Mar 2, 2026—-$0.74-$0.76-2.7%——
Nov 5, 2025—-$0.81-$0.76+6.2%——
Jul 28, 2025—-$0.99-$0.97+2.0%——
May 8, 2025—-$0.88-$1.05-19.3%——
Feb 27, 2025—-$0.92-$0.88+4.3%——

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
15
Buy
1
Hold
1
Sell
12-month analyst target
$36.88
+114.89% versus current price
Based on 17 analyst observations. Targets are estimates, not predictions.
Low target
$26.00
+51.52% vs latest price
Average target
$36.88
+114.89% vs latest price
High target
$50.00
+191.38% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 1, 2027

Next known earnings or reporting date.

EPS estimate-$1.00

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score52

Where event reaction would show up first.

AIQ score48/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
17
Average target
$36.88
Target upside
114.89%
Target range
$26.00 - $50.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
0
seekingalpha.com · Sep 30, 2026

Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN)

Dyne Therapeutics is reiterated as a "risky Buy" following a >30% stock decline, presenting a contrarian opportunity. Click for this DYN stock update.

gurufocus.com · Sep 30, 2026

DYN Maintained by Chardan Capital -- Price Target Holds at $38

Dyne Therapeutics (DYN) Analyst Rating Update On October 3, 2023, Dyne Therapeutics (DYN) received a "Buy" rating from Chardan Capital, with a maintained pri

gurufocus.com · Sep 29, 2026

DYN Reiterated by Piper Sandler -- Price Target Maintained at $47.00

Dyne Therapeutics (DYN) Analyst Rating Update On October 3, 2023, Dyne Therapeutics (DYN) received a reiteration of its Overweight rating from analyst Edward

rttnews.com · Sep 8, 2026

Dyne Therapeutics Stock Plunges 23% Despite Upcoming Long-Term Clinical Data

Dyne Therapeutics Inc. (DYN) shares are currently trading at $18.60, down $5.68, or 23.39 percent on Tuesday, despite the company announcing plans to present additional one-year clinical data from its Phase 1/2 ACHIEVE trial of zeleciment basivarsen for myotonic dystrophy type 1 (DM1).

Open full news and sentiment

DYN Catalysts FAQ

What are the next catalysts for DYN stock?

DYN's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move DYN stock?

Upcoming events that could move DYN include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could DYN's next earnings report affect the stock?

DYN's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive DYN stock higher?

DYN could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt DYN stock?

DYN could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.